About: 7 Antisense Oligonucleotides and RNA Interference

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 7 Antisense Oligonucleotides and RNA Interference Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	7 Antisense Oligonucleotides and RNA Interference
Creator	Kher, Gitanjali Misra, Ambikanandan Trehan, Sonia
source	Elsevier; PMC
abstract	Antisense technology presents an opportunity to manipulate gene expression within the cells to treat various diseases, and acts as a powerful tool for studying gene function utilizing antisense agents to manage the diseases by regulating the expression of the specific factor that actually causes the particular disease. Highly specific and effective gene silencing of any disease can be achieved by an accurate knowledge of the target mRNA sequence and rational design of its complementary antisense agents for the downregulation of its protein message. This technology has been successfully used for the treatment of cancer, HIV, and other mutating viral diseases. The technology uses agents like antisense oligonucleotides, ribozymes, short interfering RNA (siRNA), microRNA (miRNA), apatamers, and others. The purpose of this chapter is to survey different antisense technologies and the various mechanisms of gene silencing. The chapter also highlights therapeutic limitations, benefits, clinical applications, and various advances to meet delivery challenges of these agents, and gives due consideration to the regulatory and patent aspects.
has issue date	2011-12-31(xsd:dateTime)
bibo:doi	10.1016/b978-0-12-384964-9.00007-4
has license	els-covid
sha1sum (hex)	4313392632003fd093fa58560b6bde2991396215
schema:url	https://doi.org/10.1016/b978-0-12-384964-9.00007-4
resource representing a document's title	7 Antisense Oligonucleotides and RNA Interference
has PubMed Central identifier	PMC7150054
schema:publication	Challenges in Delivery of Therapeutic Genomics and Proteomics
resource representing a document's body	covid:4313392632003fd093fa58560b6bde2991396215#body_text
is schema:about of	named entity 'Antisense' named entity 'ANTISENSE OLIGONUCLEOTIDES' named entity 'RNA INTERFERENCE' named entity 'Antisense Oligonucleotides' named entity 'morpholino' named entity 'RNase' named entity 'buffering agent' named entity 'Antisense technology' named entity 'anionic' named entity 'oligonucleotides' named entity 'electroporation' named entity 'liposomes' named entity 'therapeutic agents' named entity 'protein expression' named entity 'RNA' named entity 'lipid' named entity 'transfection' named entity 'multivalent' named entity 'metabolites' named entity 'methacrylamide' named entity 'body weight' named entity 'transfection' named entity 'mRNA' named entity 'Phosphorothioates' named entity 'enzyme complex' named entity 'antisense technology' named entity 'nucleotides' named entity 'protein' named entity 'cationic' named entity 'miRNA' named entity 'antisense' named entity 'polyethylenimine' named entity 'siRNA' named entity 'phosphorus' named entity 'oligonucleotides' named entity 'mutagenic' named entity 'genome' named entity 'human genome' named entity 'RNase' named entity 'route of administration' named entity 'organ' named entity 'dendritic structures' named entity 'Aptamers' named entity 'nucleotides' named entity 'proto-oncogene' named entity 'mutagenic' named entity 'RNA' named entity 'molecule' named entity 'RNAi' named entity 'polymer' named entity 'miRNA' named entity 'cell membrane' named entity 'endogenous genes' named entity 'siRNA' named entity 'eye diseases' named entity 'RNA' named entity 'organ' named entity 'phosphorothioate' named entity 'blood pressure' named entity 'siRNA' named entity 'hemolytic' named entity 'Gene silencing' named entity 'oligonucleotide' named entity 'endogenous' named entity 'cellular uptake' named entity 'gene silencing' named entity 'cellular processes' named entity 'albumin' named entity 'biological systems' named entity 'tumors' named entity 'RNA' named entity 'endothelial cells' named entity 'anionic' named entity 'Hydrogels' named entity 'mRNA' named entity 'clinical phases' named entity 'oligonucleotides' named entity 'polymers' named entity 'SARS' named entity 'lipids' named entity 'mRNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software